Advancing a safe,
chronic therapy
for gastroparesis

Learn More ▼

Approach

CinDome Pharma, a CinRx portfolio company, is advancing deudomperidone (CIN-102) for the treatment of chronic gastroparesis. Gastroparesis, or delayed gastric emptying, occurs when the stomach does not empty normally, causing abdominal discomfort, severe nausea, or vomiting after eating. These symptoms can be hard to manage and lead to other complications.

An estimated 12-16 million people in the United States alone experience symptoms of gastroparesis and there is no long-term treatment for this debilitating condition. The incidence is growing on pace with type 2 diabetes.

Deudomperidone is a novel formulation of a well-known dopamine D2/D3 antagonist. Deudomperidone was designed to improve safety while maintaining the efficacy of domperidone, which has both prokinetic and antiemetic effects with no anticholinergic activity.

There is a lack of safe, well-tolerated and chronic treatments for gastroparesis.

Metoclopramide, the only FDA-approved, short-term medicine in the U.S., carries a black box warning due to the risk of tardive dyskinesia as it crosses the blood brain barrier.

Domperidone is the first-line treatment outside of the U.S. and is available only for short-term use. Domperidone is not approved in the U.S. in part due to a perceived cardiovascular risk associated with QT prolongation.

Deudomperidone

Candidate
Pre-Clinical
Phase 1
Phase 2
Phase 3

Mechanism of Action

Deudomperidone (CIN-102) is a new chemical entity based on the deuteration and novel formulation of domperidone, designed to provide sustained efficacy while reducing cardiac risk. It is a well-known dopamine D2/D3 antagonist with both prokinetic and antiemetic effects and no anticholinergic activity. Unlike domperidone (which is not FDA-approved in the U.S. due to QT prolongation concerns), deudomperidone has demonstrated no meaningful impact on QT at therapeutic doses.

Phase 2 Clinical Trials

CinDome is currently advancing two Phase 2 studies to evaluate the efficacy and safety of CIN-102 in adults:

envision3D

Diabetic Gastroparesis

A randomized, double-blind, placebo-controlled trial evaluating CIN-102 over a 12-week treatment period.

View on ClinicalTrials.gov ↗
envision GI Logo

Idiopathic Gastroparesis

A randomized, double-blind, placebo-controlled trial evaluating CIN-102 in adults with idiopathic gastroparesis.

View on ClinicalTrials.gov ↗

Mechanism of Action

Deudomperidone (CIN-102) is a new chemical entity based on the deuteration and novel formulation of domperidone, designed to provide sustained efficacy while reducing cardiac risk. It is a well-known dopamine D2/D3 antagonist with both prokinetic and antiemetic effects and no anticholinergic activity. Unlike domperidone (which is not FDA-approved in the U.S. due to QT prolongation concerns), deudomperidone has demonstrated no meaningful impact on QT at therapeutic doses.

Phase 2 Clinical Trials

CinDome is currently advancing two Phase 2 studies to evaluate the efficacy and safety of CIN-102 in adults:

envision3D

Diabetic Gastroparesis

A randomized, double-blind, placebo-controlled trial evaluating CIN-102 over a 12-week treatment period.

View on ClinicalTrials.gov ↗
envision GI Logo

Idiopathic Gastroparesis

A randomized, double-blind, placebo-controlled trial evaluating CIN-102 in adults with idiopathic gastroparesis.

View on ClinicalTrials.gov ↗

CinDome Team

CinDome Pharma is a CinRx portfolio company. CinRx deploys a hub-and-spoke approach in advancing its portfolio of multiple biotechnology companies, each rapidly developing high-impact medicines for patients in need.

The CinDome team consists of the scientific, technical and clinical development experts from its central team at CinRx Pharma.

For more information about the CinRx model, to meet the team or to view the entire portfolio, visit CinRx.com.

Scientific Advisory Board

Brad Kuo, M.D.

Massachusetts General Hospital

Richard McCallum, M.D.

Texas Tech University Health Sciences

Henry Parkman, M.D.

Temple University Hospital

Investors

News

Press Releases

March 17, 2026

CinDome Pharma Announces Completion of Enrollment in the envisionGI Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Idiopathic Gastroparesis

September 3, 2025

CinDome Pharma Announces Enrollment Completion in the envision3D Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis

June 4, 2025

CinDome Pharma Announces First Patient Dosed in the envisionGI Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Idiopathic Gastroparesis

View More ›
CinDome News

Publications & Presentations

Recent Publication

Results of a Phase 1 Study Assessing the Effect of CIN-102, a Novel Formulation of the Dopamine Receptor Antagonist Domperidone Designed to Treat Gastroparesis, on Cardiac Repolarization in Healthy Volunteers

May 2023 | Digestive Disease Week® Conference

The results of a phase I study assessing the effects of CIN-102 (a novel formulation of the dopamine receptor antagonist domperidone designed to treat gastroparesis) on cardiac repolarization in healthy subjects

View More ›

Contact

Interested in learning more about our pipeline of a high-impact gastrointestinal treatment, or joining our team? Connect with us through our contact form.